Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

Mutated USP45 deubiquitinates ERCC1. 2 / 2

| 2

➶

reach

"Importantly, we find that the USP45 mutant [Asp25Ala, Glu26Ala] that is catalytically active but that can not bind to ERCC1 (Supplementary Fig S5A) failed to deubiquitylate ERCC1 in vitro, indicating that specific interaction between ERCC1 and USP45 is essential to trigger deubiquitylation."

25538220

➶

reach

"Importantly, the USP45 mutant [Asp25Ala, Glu26Ala] that displays the same intrinsic catalytic activity as wild-type USP45 when assayed using a generic ubiquitin-rhodamine substrate (XREF_SUPPLEMENTARY), but that can not bind ERCC1, failed to deubiquitylate ERCC1 in parallel experiments (Fig XREF_FIG C, XREF_SUPPLEMENTARY)."

25538220

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...